Five Prime Therapeutics (FRPX) PT Raised to $60 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Five Prime Therapeutics (FPRX) Pipeline on Track, Leerink Says; PT to $58
August 5, 2016 8:16 AM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and raised his price target on Five Prime Therapeutics (NASDAQ: FPRX) to $58.00 (from $45.00) following Q2 updated with the pipeline on track.
Schmidt commented, "We updating our estimates to reflect 2Q16 financial results and are maintaining our OP rating on FPRX shares despite the recent... More
Five Prime Therapeutics (FPRX) Tops Q2 EPS by 7c
August 4, 2016 5:38 PM EDTFive Prime Therapeutics (NASDAQ: FPRX) reported Q2 EPS of ($0.49), $0.07 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $9.92 million versus the consensus estimate of $6.38 million.
"Were pleased with the progress weve made through the first half of the year and... More
